Fig 6.

Monte Carlo simulations displaying the distribution of fAUCs based on previously published population pharmacokinetic analysis from the linezolid compassionate-use trials (20). All patients in the previously published study received 600 mg q12h. A protein binding level of 31% was utilized to calculate the 24-h free-drug AUC from the total AUC in the population PK study. The simulated doses studied in the in vitro hollow-fiber model are within this distribution and are overlaid as symbols.